{
  "id": 6613534,
  "title": "FDA places partial hold on Biohaven’s epilepsy drug",
  "url": "https://urgent.news/2026/09/10/fda-places-partial-hold-on-biohavens-epilepsy-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-10T16:13:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/biohaven-fda-hold-opakalim-epilepsy-drug-trial/830013/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "FDA places partial hold on Biohaven's ion channel drug",
        "url": "https://urgent.news/2026/09/10/fda-places-partial-hold-on-biohavens-ion-channel-drug",
        "published": "2026-09-10T13:58:04.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}